The merger plans underscore Bristol-Myers and Celgene’s efforts to diversify in the field of cancer treatments, with investors in recent months questioning their growth prospectsfrom homepage http://bit.ly/2F8cSjF
Friday, January 4, 2019
Bristol-Myers Squibb to buy Celgene in $74 billion deal
The merger plans underscore Bristol-Myers and Celgene’s efforts to diversify in the field of cancer treatments, with investors in recent months questioning their growth prospectsfrom homepage http://bit.ly/2F8cSjF
Posts
0 comments:
Post a Comment